New Possibilities in the Therapeutic Approach to Alzheimer’s Disease

Abstract

Despite the fact that Alzheimer’s disease (AD) is the most common cause of dementia, after many years of research regarding this disease, there is no casual treatment. Regardless of the serious public health threat it poses, only five medical treatments for Alzheimer’s disease have been authorized, and they only control symptoms rather than changing the course of the disease. Numerous clinical trials of single-agent therapy did not slow the development of disease or improve symptoms when compared to placebo. Evidence indicates that the pathological alterations linked to AD start many years earlier than a manifestation of the disease. In this pre-clinical period before the neurodegenerative process is established, pharmaceutical therapy might prove invaluable. Although recent findings from the testing of drugs such as aducanumab are encouraging, they should nevertheless be interpreted cautiously. Such medications may be able to delay the onset of dementia, significantly lowering the prevalence of the disease, but are still a long way from having a clinically effective disease-modifying therapy.

Differential Diagnosis of Alzheimer Disease vs. Mild Cognitive Impairment Based on Left Temporal Lateral Lobe Hypomethabolism on 18F-FDG PET/CT and Automated Classifiers

“…Our paper confirms the clinical value of 18 F-FDG brain PET/CT as an essential diagnostic first step to contribute to the differential diagnosis of dementia disorders also in the amyloid PET and biological markers (i.e., amyloid and tau protein) era since, as it is well known, accurate and early diagnosis of Alzheimer disease in respect of Mild Cognitive Impairment is crucial for improving the condition of patients. The combined use of semi-quantitative analysis of 18 F-FDG PET and automatic classification seems to be a supportive tool for clinical diagnosis in order to consider effective preventive early measures to delay the appearance of the full-blown disease or to suggest further investigations such as amyloid PET or more advanced treatments and therapeutic approaches [ 52 , 53 ].…”

Advances in Comprehensive Treatment of the Alzheimer's Disease

“…Curcumin inhibition A β The aggregation mechanism may be in A β The specific mechanism of a link after generation needs to be further studied. In general, animal studies have shown promising findings on the physiological and behavioral enhancement of cognition [7]. The effectiveness in human body needs to be further explored.…”

Ethical Issues of Primary and Secondary Dementia Prevention

“…Blood-based biomarkers have an advantage in this regard, but to date, they do not achieve the same accuracy; there is still no certainty whether or when an asymptomatic person with an elevated biomarker level might develop AD symptoms. However, a combination of blood-based biomarkers has a good chance of achieving the same accuracy as PET or CSF biomarkers in the near future (Doroszkiewicz & Mroczko, 2022).…”